Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Merck Sharp & Dohme LLC, Foundation Medicine, Myriad Genetics, Inc..
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
43actual
Sites
35
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-29 | actual | When the study began enrolling |
| Primary completion | 2024-10-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-13 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-19 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: olaparib — also filed as Lynparza
- Drug: enzalutamide — also filed as XTANDI
- Drug: abiraterone acetate — also filed as ZYTIGA
- Drug: Prednisone
Primary outcome
what the primary-completion date above is the date OFRadiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)
measured Tumor assessments every 8 weeks (± 1 week) relative to the date of randomization until radiological progression as assessed by BICR or death (median duration of treatment of 9 and 6 months for Olaparib and Investigators Choice of NHA respectively).
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-04-13 · 2.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-09-23 · 9.3 MB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed